The move is aimed to strengthen LGC's clinical quality controls
LGC has announced its acquisition of Technopath Clinical Diagnostics.
The acquisition augments LGC’s position in the clinical diagnostics QC market, adding to its manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.
Euan O’Sullivan, President & COO, LGC, said: “We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC. Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”
Malcolm Bell, CEO, Technopath Clinical Diagnostics, commented: “We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit. Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”
Technopath Clinical Diagnostics operates from Tipperary, Ireland, and currently has more than 100 employees. Its QC and software products are used by laboratories in over 120 countries.
The company is also ISO 13485 certified and has successfully achieved international regulatory market approvals including IVD 98/79/EC, Europe CE Mark, US FDA 510K, and accreditations in Canada, China, Brazil and Australia, among others.